CL2020001930A1 - Compuestos para el tratamiento de trastornos dependientes de cinasas. - Google Patents

Compuestos para el tratamiento de trastornos dependientes de cinasas.

Info

Publication number
CL2020001930A1
CL2020001930A1 CL2020001930A CL2020001930A CL2020001930A1 CL 2020001930 A1 CL2020001930 A1 CL 2020001930A1 CL 2020001930 A CL2020001930 A CL 2020001930A CL 2020001930 A CL2020001930 A CL 2020001930A CL 2020001930 A1 CL2020001930 A1 CL 2020001930A1
Authority
CL
Chile
Prior art keywords
compounds
kinase
treatment
dependent disorders
compositions containing
Prior art date
Application number
CL2020001930A
Other languages
English (en)
Inventor
Lynne Canne Bannen
Minna Bui
Faming Jiang
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CL2020001930A1 publication Critical patent/CL2020001930A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen en la presente compuestos de la Fórmula I’, inhiben, regulan y/o modulan el receptor de cinasa, particularmente las vías de transducción de señales de Axl y Mer relacionadas con los cambios en las actividades celulares mencionados anteriormente, las composiciones que contienen estos compuestos y los métodos para usarlos para el tratamiento de enfermedades y afecciones dependientes de cinasas. La presente invención también proporciona métodos para la confección de compuestos mencionados anteriormente, y composiciones que contienen estos compuestos.
CL2020001930A 2018-01-26 2020-07-23 Compuestos para el tratamiento de trastornos dependientes de cinasas. CL2020001930A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622629P 2018-01-26 2018-01-26
US201862622626P 2018-01-26 2018-01-26

Publications (1)

Publication Number Publication Date
CL2020001930A1 true CL2020001930A1 (es) 2020-12-11

Family

ID=65409542

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001930A CL2020001930A1 (es) 2018-01-26 2020-07-23 Compuestos para el tratamiento de trastornos dependientes de cinasas.

Country Status (18)

Country Link
US (2) US11708367B2 (es)
EP (1) EP3743068A1 (es)
JP (2) JP7307733B2 (es)
KR (1) KR20200124678A (es)
CN (1) CN112312909A (es)
AU (1) AU2019212719A1 (es)
BR (1) BR112020015199A2 (es)
CA (1) CA3088127A1 (es)
CL (1) CL2020001930A1 (es)
CO (1) CO2020010467A2 (es)
CR (1) CR20200355A (es)
IL (2) IL302626A (es)
MA (1) MA51672A (es)
MX (2) MX2020007759A (es)
PE (1) PE20210044A1 (es)
PH (1) PH12020551059A1 (es)
SG (1) SG11202006945PA (es)
WO (1) WO2019148036A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936487A (zh) 2018-01-26 2020-11-13 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CR20230287A (es) * 2018-01-26 2023-07-26 Exelixis Inc COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358)
EP3743068A1 (en) * 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
CN115244041A (zh) * 2020-03-10 2022-10-25 南京明德新药研发有限公司 乙烯基取代吡啶类化合物
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
JP3088018B2 (ja) 1995-03-30 2000-09-18 ファイザー・インコーポレーテッド キナゾリン誘導体
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BRPI0412262A (pt) 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
SI2392565T1 (sl) * 2003-09-26 2014-05-30 Exelixis, Inc. c-Met modulatorji in postopki uporabe
US7314622B2 (en) 2005-04-15 2008-01-01 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
JP2009529047A (ja) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環系ピラゾール化合物およびその使用
RU2011119478A (ru) * 2008-10-14 2012-11-27 Нин Си Соединения и способы применения
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120322075A1 (en) 2009-10-26 2012-12-20 Externautics S.P.A. Lung Tumor Markers and Methods of Use Thereof
EP2494351B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Colon and rectal tumor markers and methods of use thereof
EP2494362B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Prostate tumor markers and methods of use thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
US20130017546A1 (en) 2009-10-26 2013-01-17 Externautics S.P.A. Breast Tumor Markers and Methods of Use Thereof
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
JP5770281B2 (ja) * 2010-07-14 2015-08-26 ベータ ファーマシューティカルズ カンパニー リミテッド ｃ−ＭＥＴチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SI2992017T1 (sl) 2013-05-02 2021-04-30 Anaptysbio, Inc. Protitelesa, usmerjena proti programirani smrti-1 (PD-1)
WO2014198919A2 (en) 2013-06-14 2014-12-18 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
CN105828834A (zh) 2013-11-05 2016-08-03 同源生物服务股份有限公司 检查点抑制剂和治疗剂的组合以治疗癌症
AU2015249232B2 (en) 2014-04-25 2020-06-25 Exelixis, Inc. Method of treating lung adenocarcinoma
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品（宁波）有限公司 一种防老化阳光面料
CN110437145A (zh) 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
SG11202005719UA (en) 2017-12-20 2020-07-29 Angex Pharmaceutical Inc Carbamate and urea compounds as multikinase inhibitors
EP3743068A1 (en) * 2018-01-26 2020-12-02 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Also Published As

Publication number Publication date
IL302626A (en) 2023-07-01
US20210040099A1 (en) 2021-02-11
KR20200124678A (ko) 2020-11-03
WO2019148036A1 (en) 2019-08-01
CO2020010467A2 (es) 2020-10-30
MA51672A (fr) 2020-12-02
EP3743068A1 (en) 2020-12-02
AU2019212719A1 (en) 2020-08-20
JP2021511359A (ja) 2021-05-06
JP7307733B2 (ja) 2023-07-12
US20230374024A1 (en) 2023-11-23
PH12020551059A1 (en) 2021-05-31
SG11202006945PA (en) 2020-08-28
PE20210044A1 (es) 2021-01-08
JP2023082042A (ja) 2023-06-13
BR112020015199A2 (pt) 2021-05-04
IL276028A (en) 2020-08-31
MX2020007759A (es) 2020-09-24
CA3088127A1 (en) 2019-08-01
MX2022014351A (es) 2022-12-13
CN112312909A (zh) 2021-02-02
CR20200355A (es) 2021-02-22
US11708367B2 (en) 2023-07-25

Similar Documents

Publication Publication Date Title
CL2020001931A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CL2020001930A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
CO2020013601A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
MX2020004534A (es) Moduladores de la vía integrada del estrés.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CO2021003036A2 (es) Compuestos de anillo fusionado
CL2019001988A1 (es) Compuestos químicos como inhibidores de actividad interleuquina-2.
PE20200335A1 (es) Compuestos que inhiben la proteina mcl-1
MX2020004538A (es) Moduladores de la vía de estrés integrada.
CO2021006098A2 (es) Moduladores de profármacos de la vía de estrés integrada
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
EA202091803A1 (ru) Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CA3139156A1 (en) Compounds for the treatment of kinase-dependent disorders
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
CL2021000282A1 (es) Inhibidores de ckd8/19
UY38133A (es) Nuevos inhibidores de cdk8/19
EA202091789A1 (ru) Соединения для лечения киназозависимых расстройств